Khiron Life Sciences Corp. (KHRNF)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Apr 30, 2025
Khiron Life Sciences Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
Period Ending | Sep '22 Sep 30, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
| Revenue | 16.14 | 12.8 | 8.02 | 9.58 | 0.89 | - |
| Revenue Growth (YoY) | 38.20% | 59.60% | -16.34% | 974.64% | - | - |
| Cost of Revenue | 9.47 | 6.42 | 1.01 | 7.15 | 0.59 | - |
| Gross Profit | 6.67 | 6.37 | 7.01 | 2.44 | 0.3 | - |
| Selling, General & Admin | 21.82 | 25.18 | 29.09 | 25.31 | 15.28 | 3.31 |
| Research & Development | 1.75 | 1.22 | 1.53 | 3.73 | 0.35 | - |
| Operating Expenses | 24.11 | 26.89 | 30.61 | 38.42 | 18.92 | 4.52 |
| Operating Income | -17.44 | -20.52 | -23.61 | -35.98 | -18.63 | -4.52 |
| Interest Expense | -0.45 | -0.31 | -0.36 | - | - | - |
| Currency Exchange Gain (Loss) | -1.5 | -1.02 | -0.02 | - | - | - |
| Other Non Operating Income (Expenses) | 2.8 | 2.73 | 0.04 | -0.21 | -1.1 | -0.02 |
| EBT Excluding Unusual Items | -16.59 | -19.13 | -23.95 | -36.19 | -19.73 | -4.54 |
| Merger & Restructuring Charges | - | - | - | -1.21 | - | - |
| Asset Writedown | -14.44 | -14.47 | - | - | - | - |
| Other Unusual Items | - | - | - | 1.04 | - | - |
| Pretax Income | -31.03 | -33.59 | -23.95 | -36.36 | -19.73 | -4.54 |
| Income Tax Expense | -0.37 | -0.47 | 0.09 | 0.02 | 0.08 | - |
| Net Income | -30.66 | -33.13 | -24.04 | -36.38 | -19.81 | -4.54 |
| Net Income to Common | -30.66 | -33.13 | -24.04 | -36.38 | -19.81 | -4.54 |
| Shares Outstanding (Basic) | 190 | 165 | 120 | 102 | 49 | 28 |
| Shares Outstanding (Diluted) | 190 | 165 | 120 | 102 | 49 | 28 |
| Shares Change (YoY) | 24.67% | 36.76% | 17.97% | 110.16% | 74.80% | - |
| EPS (Basic) | -0.16 | -0.20 | -0.20 | -0.36 | -0.41 | -0.16 |
| EPS (Diluted) | -0.16 | -0.20 | -0.20 | -0.36 | -0.41 | -0.16 |
| Free Cash Flow | -17.62 | -22.14 | -27.23 | -36.17 | -18.6 | -3.2 |
| Free Cash Flow Per Share | -0.09 | -0.14 | -0.23 | -0.35 | -0.38 | -0.12 |
| Gross Margin | 41.34% | 49.79% | 87.41% | 25.42% | 33.35% | - |
| Operating Margin | -108.07% | -160.40% | -294.44% | -375.48% | -2088.78% | - |
| Profit Margin | -190.00% | -258.92% | -299.85% | -379.63% | -2221.27% | - |
| Free Cash Flow Margin | -109.17% | -173.07% | -339.60% | -377.46% | -2085.93% | - |
| EBITDA | -16.41 | -19.72 | -22.98 | -35.48 | -18.29 | -4.52 |
| EBITDA Margin | -101.67% | -154.12% | -286.67% | - | - | - |
| D&A For EBITDA | 1.03 | 0.8 | 0.62 | 0.5 | 0.34 | 0 |
| EBIT | -17.44 | -20.52 | -23.61 | -35.98 | -18.63 | -4.52 |
| EBIT Margin | -108.07% | -160.40% | -294.44% | - | - | - |
| Revenue as Reported | 16.14 | 12.8 | 8.02 | 9.58 | 0.89 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.